Stockreport

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma [Yahoo! Finance]

Immuneering Corporation - Class A  (IMRX) 
PDF - IMM-1-104 was observed to be uniquely well tolerated in Phase 1 data shared at ESMO 2024, relative to MEK inhibitors currently used to treat melanoma - - Melanoma p [Read more]